4-methoxyheptane | 90951-65-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methoxyheptane
• CAS: 90951-65-8
• 化学式: C₈H₁₈O
• 分子量: 130.23
• InChiKey: XUMCXZGPFPOTEX-UHFFFAOYSA-N

物化性质

• 沸点：
  132.6±8.0 °C(Predicted)
• 密度：
  0.778±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-庚酮 在 lead(IV) acetate 作用下， 以 正戊烷 、 苯 为溶剂， 反应 8.0h， 生成 4-methoxyheptane
  参考文献：
  名称：

  Chemistry and Kinetics of Dipropylcarbene in Solution

  摘要：

  The photochemistry of 2-methoxy-2-methyl-5,5-dipropyl-Delta(3)-1,3,4-oxadiazoline (1a) and 2,2-dimethoxy-5,5-dipropyl-Delta(3)-1,3,4-oxadiazoline (1b) was investigated. Photolysis (300 nm) of these compounds in solution leads to fragmentation to 4-diazoheptane (major), which slowly forms the corresponding azine. Fragmentation to form 4-heptanone is also observed. Yields of 4-diazoheptane in CH2Cl2 are much larger than those in pentane. 4-Diazoheptane can be trapped with 1-pentene to form a pyrazoline or with methanol to form 4-methoxyheptane. The pyrazoline can be decomposed photochemically to form 1,1,2-tripropylcyclopropane. In solution, 4-diazoheptane is inefficiently photolyzed to dipropylcarbene (DPC), which can be trapped with piperidine or with pyridine in laser flash photolysis experiments. Analysis of the piperidine and pyridine data indicates that the lifetime of DPC in cyclohexane, methylene chloride, or Freon-113 (CF2ClCFCl2) solution at ambient temperature is controlled by 1,2 hydrogen migration to form Z- and E-3-heptene. The lifetime deduced under these conditions is approximate to 300 ps, which is about 20-fold shorter than that of dimethylcarbene in perfluorohexane at ambient temperature. Upon photolysis (254 nm) of oxadiazoline 1a in argon, 4-diazoheptane and 1-methoxydiazoethane are formed. These diazo compounds undergo subsequent photolysis that revealed the formation of methoxy(methyl)carbene and E- and Z-3-heptene. It was not possible to detect DPC in argon at 14 K.

  DOI：

  10.1021/jp990198d

文献信息

• [EN] VEGFR3 INHIBITORS<br/>[FR] INHIBITEURS DE VEGFR3
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014026242A1

  公开（公告）日：2014-02-20

  This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

  本发明涉及式(I)的化合物。该发明还涉及制备式(I)化合物的方法，含有该化合物的药物或组合物，以及利用该化合物治疗增殖性疾病（如癌症）以及通过控制和/或抑制淋巴管生成改善疾病的方法。
• [EN] 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE LA 7-ARYL-1,2,4-TRIAZOLO [4,3-A] PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010130423A1

  公开（公告）日：2010-11-18

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型Formula (I)的三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2 ("mGluR2")的阳性变构调节剂，适用于治疗或预防与谷氨酸功能障碍有关的神经和精神疾病，以及mGluR2代谢型受体亚型参与的疾病。本发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物预防或治疗与mGluR2有关的神经和精神疾病和疾病的用途。
• NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE
  申请人：DAINIPPON SUMITOMO PHARMA CO., LTD.

  公开号：US20140121243A1

  公开（公告）日：2014-05-01

  A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): wherein A is CR 1E or a nitrogen atom, X—Y—Z is N—CO—NR 3A R 3B and the like, R 1A to R 1E are each independently a hydrogen atom and the like, R 2A to R 2D are each independently a hydrogen atom and the like, R 3A and R 3B are each independently an optionally-substituted C 3-10 cycloalkyl and the like, and n is 1 or 2 or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).

  一种用于治疗与中枢神经系统（CNS）和/或外周神经系统（PNS）中胆碱能特性相关疾病、与平滑肌收缩相关疾病、内分泌紊乱、神经退行性疾病等的药物，其中包括化合物Formula（I）：其中A为CR1E或氮原子，X—Y—Z为N—CO—NR3AR3B等，R1A到R1E各自独立地为氢原子等，R2A到R2D各自独立地为氢原子等，R3A和R3B各自独立地为选择性取代的C3-10环烷基等，n为1或2或其药学上可接受的盐，具有对α7烟碱乙酰胆碱受体（α7 nAChR）活性的强效调节作用。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：Wong Norman C.W.

  公开号：US20090259048A1

  公开（公告）日：2009-10-15

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了一些非自然生成的多酚化合物，它们可以上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关的疾病，如动脉粥样硬化等。